Supplemental Digital Content 2: Table Participant characteristics of phenotypic HCM patients according to genotype status.

	Total (n=80)	**Genotype + (N=44)**	**Genotype - (N=36)**	***P*-value**
Physical activity volume				
Total physical activity, MET-hrs/week	14 [9-22]	15 [10-24]	13 [5-20]	.06
During adolescence, MET-hrs/week	20 [9-31]	21 [12-31]	19 [7-30]	.35
Pre-diagnosis, MET-hrs/week	15 [9-24]	16 [10-29]	13 [5-20]	.06
Post-diagnosis, MET-hrs/week	7 [0-19]	12 [1-23]	3 [0-15]	.05
Sports-related, MET-hrs/week	8 [2-14]	9 [2-14]	4 [1-13]	.21
Transportation, MET-hrs/week	7 [3-11]	8 [4-12]	6 [2-9]	.15
Participant characteristics				
Age at participation, years	54 ± 15	51 ± 14	57 ± 17	.11
Gender, Male (%)	44 (55%)	23 (52%)	21 (58%)	.59
Age at diagnosis, years	47 ± 16	43 ± 15	53 ± 16	.01*
Pathogenic mutation present, n (%)	44 (55%)	44 (100%)	0 (0%)	<.001*
Cardiovascular risk factors				
Hypertension, n (%)	37 (46%)	15 (34%)	22 (61%)	.02*
Current smoker, n (%)	16 (20%)	8 (18%)	8 (22%)	.65
Dyslipidaemia, n (%)	19 (24%)	9 (21%)	10 (28%)	.44
Diabetes, n (%)	4 (5%)	1 (2%)	3 (8%)	.22
Recent creatinine, μmol/L	85 ± 17	83 ± 17	88 ± 16	.20
Systolic blood pressure, mmHg	132 ± 24	128 ± 21	136 ± 26	.12
Heart rate, beats/minute	74 ± 14	70 ± 12	78 ± 15	.01*
History of atrial fibrillation, n (%)	12 (15%)	5 (11%)	7 (19%)	.31
Framingham 10-year heart risk, %	14 [4-26]	10 [3-22]	17 [7-33]	.03*

Elevated troponin, >14 ng/L, n (%)	16 (21%)	8 (19%)	8 (24%)	.59
Risk factors for SCD				
Aborted cardiac arrest / sustained VT, n (%)	2 (3%)	1 (2%)	1 (3%)	>.99
Family history of SCD, n (%)	14 (18%)	12 (27%)	2 (6%)	.01*
Syncope, n (%)	1 (1%)	1 (2%)	0 (0%)	>.99
Non-sustained VT (holter) , n (%)	16 (22%)	12 (29%)	4 (12%)	.08
Abnormal blood pressure response, n (%)	13 (17%)	7 (16%)	6 (17%)	.96
Maximal wall thickness ≥30mm, n (%)	2 (3%)	1 (2%)	1 (3%)	>.99
Symptoms				
Chest pain, n (%)	12 (15%)	8 (18%)	4 (11%)	.38
Dyspnea (NYHA class ≥ II) , n (%)	39 (49%)	20 (46%)	19 (53%)	.51
Therapy				
Beta-blocker, n (%)	41 (51%)	21 (48%)	20 (56%)	.49
Calciumantagonist, n (%)	11 (14%)	6 (14%)	5 (14%)	>.99
ICD, n (%)	8 (10%)	6 (14%)	2 (6%)	.28
Echocardiography				
LV outflow tract gradient ≥30 mmHg, n (%)	15 (19%)	6 (14%)	9 (25%)	.21
Systolic anterior motion mitral valve, n (%)	32 (41%)	15 (34%)	17 (49%)	.19
Left atrial diameter, mm	43 [39-49]	43 [39-50]	44 [38-48]	.81
CMR Imaging	N=68	N=36	N=32	
Maximal LV wall thickness, mm	18 ± 5	18 ± 5	17 ± 5	.60
LV end-diastolic volume, ml	184 ± 41	186 ± 36	181± 47	.68
LV ejection fraction, %	60 ± 8	59 ± 8	60 ± 7	.49
LV Mass index, g/m^2	64 [54-81]	64 [51-78]	66 [55-87]	.33
LGE present, n (%)	38 (57%)	24 (69%)	14 (44%)	.04*
LGE extent, % of LV mass	1 [0-7]	3 [0-10]	0 [0-6]	.07

MET, Metabolic Equivalent of Task. SCD, sudden cardiac death; VT, Ventricular Tachycardia; NYHA, New York Heart Association Functional classification; LV, Left Ventricular; CMR, cardiac magnetic resonance; LGE, Late Gadolinium Enhancement. Data is presented as mean ± SD, n (%) or median [interquartile range]. $^{*}P<.05$.